Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enhabit, Inc. filings document formal disclosures for a public home health and hospice care provider. Recent reports include 8-K material-event disclosures, Regulation FD materials, operating and financial results, risk-factor updates, shareholder voting matters and capital-structure information.
The company’s SEC record also covers material definitive agreements, including credit facilities and related debt terms, governance matters such as officer transitions, and litigation-related disclosures involving claims connected to its home health and hospice business history. These filings frame Enhabit’s regulatory reporting around healthcare operations, financing arrangements, corporate governance and stockholder matters.
Enhabit, Inc. (EHAB) – Form 4 insider transaction
Director Barry P. Schochet bought 15,773 shares of Enhabit common stock on 26 June 2025 at a reported price of $9.51 per share. Following the purchase, Schochet’s direct holding rose to 61,614 shares. No derivative securities were involved, and no dispositions were reported.
This acquisition increases the director’s stake by roughly 34% (15,773 ÷ 45,841 previously held) and may be interpreted by investors as a vote of confidence in the company’s prospects.
Enhabit (NYSE:EHAB) director Gregory S. Rush filed a Form 4 disclosing the open-market purchase of 15,773 common shares at $9.51 on 26 Jun 2025. After the trade, Rush directly owns 69,479 shares of EHAB.
No derivative positions or additional transactions were reported in this routine insider filing.
Enhabit (NYSE:EHAB) filed a Form 4 disclosing that director Mark W. Ohlendorf purchased 15,773 shares of common stock on 26-Jun-2025 at an average price of $9.51.
The acquisition lifts the director’s direct holdings to 37,723 shares, representing a roughly 72 % increase in his stake. No dispositions, derivative securities, or Rule 10b5-1 trading-plan indications were reported.